Market Cap | 82.38M | P/E | - | EPS this Y | 2.20% | Ern Qtrly Grth | - |
Income | -15.07M | Forward P/E | -6.54 | EPS next Y | 16.30% | 50D Avg Chg | 1.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 1.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -11.00% |
Recommedations | 2.00 | Quick Ratio | 1.97 | Shares Outstanding | 13.77M | 52W Low Chg | 11.00% |
Insider Own | 47.16% | ROA | -72.74% | Shares Float | 6.34M | Beta | - |
Inst Own | 12.19% | ROE | -147.23% | Shares Shorted/Prior | 26.69K/19.84K | Price | 6.02 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 121,382 | Target Price | 14.33 |
Oper. Margin | - | Earnings Date | - | Volume | 8,515 | Change | 0.00% |
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs in the United States. Its lead product candidate includes INT230-6, which is in human clinical studies for the treatment of refractory solid tumors, such as soft tissue sarcoma which is in phase 3 trails; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Benchmark | Speculative Buy | Jul 11, 24 |
Benchmark | Speculative Buy | May 16, 24 |
Benchmark | Speculative Buy | Mar 21, 24 |
Benchmark | Speculative Buy | Nov 14, 23 |
Benchmark | Speculative Buy | Aug 24, 23 |
Benchmark | Speculative Buy | Jul 18, 23 |